vs
Side-by-side financial comparison of NEPHROS INC (NEPH) and Peraso Inc. (PRSO). Click either name above to swap in a different company.
NEPHROS INC is the larger business by last-quarter revenue ($4.7M vs $2.9M, roughly 1.6× Peraso Inc.). NEPHROS INC runs the higher net margin — 1.3% vs -43.3%, a 44.6% gap on every dollar of revenue. On growth, NEPHROS INC posted the faster year-over-year revenue change (22.2% vs -22.0%). Over the past eight quarters, NEPHROS INC's revenue compounded faster (15.9% CAGR vs 1.0%).
Nephros Inc is a medical technology company that develops and commercializes high-performance water purification systems, infection control products, and renal care solutions. Its offerings are primarily used by hospitals, dialysis clinics, and long-term care facilities across North America to reduce waterborne pathogen risks and improve patient outcomes.
Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.
NEPH vs PRSO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.7M | $2.9M |
| Net Profit | $62.0K | $-1.2M |
| Gross Margin | 58.4% | 52.2% |
| Operating Margin | 0.4% | -44.6% |
| Net Margin | 1.3% | -43.3% |
| Revenue YoY | 22.2% | -22.0% |
| Net Profit YoY | -82.2% | 20.3% |
| EPS (diluted) | $0.01 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.7M | $2.9M | ||
| Q3 25 | $4.8M | $3.2M | ||
| Q2 25 | $4.4M | $2.2M | ||
| Q1 25 | $4.9M | $3.9M | ||
| Q4 24 | $3.9M | $3.7M | ||
| Q3 24 | $3.5M | $3.8M | ||
| Q2 24 | $3.3M | $4.2M | ||
| Q1 24 | $3.5M | $2.8M |
| Q4 25 | $62.0K | $-1.2M | ||
| Q3 25 | $337.0K | $-1.2M | ||
| Q2 25 | $237.0K | $-1.8M | ||
| Q1 25 | $558.0K | $-471.0K | ||
| Q4 24 | $349.0K | $-1.6M | ||
| Q3 24 | $183.0K | $-2.7M | ||
| Q2 24 | $-289.0K | $-4.4M | ||
| Q1 24 | $-169.0K | $-2.0M |
| Q4 25 | 58.4% | 52.2% | ||
| Q3 25 | 61.2% | 56.2% | ||
| Q2 25 | 63.2% | 48.3% | ||
| Q1 25 | 64.7% | 69.3% | ||
| Q4 24 | 64.0% | 56.3% | ||
| Q3 24 | 61.1% | 47.0% | ||
| Q2 24 | 58.8% | 55.5% | ||
| Q1 24 | 62.1% | 46.4% |
| Q4 25 | 0.4% | -44.6% | ||
| Q3 25 | 6.6% | -36.8% | ||
| Q2 25 | 5.6% | -80.0% | ||
| Q1 25 | 11.6% | -13.3% | ||
| Q4 24 | 8.2% | -44.3% | ||
| Q3 24 | 5.9% | -70.3% | ||
| Q2 24 | -9.7% | -105.6% | ||
| Q1 24 | -5.7% | -128.9% |
| Q4 25 | 1.3% | -43.3% | ||
| Q3 25 | 7.1% | -37.4% | ||
| Q2 25 | 5.4% | -82.4% | ||
| Q1 25 | 11.4% | -12.2% | ||
| Q4 24 | 9.0% | -42.4% | ||
| Q3 24 | 5.2% | -70.6% | ||
| Q2 24 | -8.9% | -104.4% | ||
| Q1 24 | -4.8% | -72.1% |
| Q4 25 | $0.01 | $-0.09 | ||
| Q3 25 | $0.03 | $-0.17 | ||
| Q2 25 | $0.02 | $-0.31 | ||
| Q1 25 | $0.05 | $-0.10 | ||
| Q4 24 | $0.04 | $0.36 | ||
| Q3 24 | $0.02 | $-0.98 | ||
| Q2 24 | $-0.03 | $-1.88 | ||
| Q1 24 | $-0.02 | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.4M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $10.2M | $4.6M |
| Total Assets | $13.6M | $6.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.4M | $2.9M | ||
| Q3 25 | $5.2M | — | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $4.1M | — | ||
| Q4 24 | $3.8M | $3.3M | ||
| Q3 24 | $2.5M | $1.3M | ||
| Q2 24 | $3.1M | $1.9M | ||
| Q1 24 | $3.6M | $2.4M |
| Q4 25 | $10.2M | $4.6M | ||
| Q3 25 | $10.0M | $3.6M | ||
| Q2 25 | $9.6M | $3.0M | ||
| Q1 25 | $9.3M | $3.6M | ||
| Q4 24 | $8.6M | $3.5M | ||
| Q3 24 | $8.2M | $2.0M | ||
| Q2 24 | $7.9M | $3.6M | ||
| Q1 24 | $8.2M | $6.7M |
| Q4 25 | $13.6M | $6.1M | ||
| Q3 25 | $13.2M | $6.2M | ||
| Q2 25 | $12.2M | $5.5M | ||
| Q1 25 | $11.8M | $6.7M | ||
| Q4 24 | $11.2M | $7.2M | ||
| Q3 24 | $10.4M | $7.2M | ||
| Q2 24 | $11.1M | $9.8M | ||
| Q1 24 | $11.4M | $11.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.71× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-1.1M | ||
| Q3 25 | $99.0K | $-1.5M | ||
| Q2 25 | $994.0K | $-2.0M | ||
| Q1 25 | $322.0K | $-966.0K | ||
| Q4 24 | $1.3M | $-687.0K | ||
| Q3 24 | $-623.0K | $-683.0K | ||
| Q2 24 | $-501.0K | $-659.0K | ||
| Q1 24 | $-672.0K | $-2.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -48.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.71× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 4.19× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 3.74× | — | ||
| Q3 24 | -3.40× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NEPH
| Products | $4.6M | 98% |
| Other | $108.0K | 2% |
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
